GlassScriptPhysician profile
Laney E Robinson
NPI 1750874087
$2,875.77
in general payments reported to CMS, 2019-2025
20 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.07 · 2021: $296 · 2022: $208 · 2023: $839 · 2024: $845 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $648.85 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $475.12 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $390.68 | 2021-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $320.77 | 2022-2025 | |
| Pfizer INC. | $234.41 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $194.22 | 2021-2022 | |
| Dexcom, INC. | $109.12 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $100.86 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $89.78 | 2020-2025 | Wegovy, Ozempic |
| Abbvie INC. | $61.63 | 2023-2025 | Vraylar |
| Mylan Specialty L.P. | $50.56 | 2022-2023 | Yupelri |
| Daiichi Sankyo INC. | $38.71 | 2022-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $38.54 | 2024-2025 | Voquezna |
| Irhythm Technologies, INC. | $23.11 | 2023 | Zio Xt Patch |
| Supernus Pharmaceuticals, INC. | $21.44 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.24 | 2021 | |
| Lilly USA, LLC | $16.82 | 2024 | Jardiance, Zepbound |
| Inspire Medical Systems, INC. | $14.96 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.31 | 2023 | Ofev |
| Teva Pharmaceuticals USA, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laney Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.